Article

CMEs 2021: A Year in Review

Author(s):

Psychiatric Times featured a wide variety of psychiatric issues in this year’s CMEs.

lenets_tan/Adobe Stock

lenets_tan/Adobe Stock

Throughout 2021, Psychiatric TimesTM worked with experts from multiple areas in psychiatry to bring you discussions of important topics, such as identifying and treating victims of human trafficking; diagnosing and managing fibromyalgia; and ethically evaluating dangerousness in individuals with personality disorders. Here are some highlights from our selection of this year’s Continuing Medication Education (CME) articles:

Psychiatric TimesTM March 2021

Psychiatric TimesTM March 2021

Psilocybin Revisited: The Science Behind the Drug and Its Surprising Therapeutic Potential

Psilocybin and psilocin are the main psychedelic agents of the psychoactive mushroom genus Psilocybe.1 Historical and cultural use of these psychoactive mushrooms dates back 3000 years in Mexico and the Southwestern regional areas of the present-day United States. Scientifically, psilocybin was isolated and identified in 1958, synthesized in 1959, and used in various experimental research studies in the early 1960s. During that time, psilocybin and other psychedelic agents such as lysergic acid diethylamide (LSD) generated considerable controversy. Outside of recreational use, could they be used safely as therapeutic interventions? Continue Reading

Psychiatric TimesTM August 2021

Psychiatric TimesTM August 2021

Fibromyalgia: What It Is and How to Treat It

Fibromyalgia (FM) is one of the most controversial diagnoses in the field of pain management. Some experts believe that it does not exist and actually represents an accidental or purposeful misdiagnosis of other conditions, while others believe that it is badly underdiagnosed.1 The truth likely falls somewhere between these 2 extremes. FM is a real syndrome, but it is also perhaps overdiagnosed, both because many physicians are unaware of the actual diagnostic criteria, and because there may be a desire to avoid diagnosing patients with other conditions that could explain the symptoms of FM—most notably mental disorders. Continue Reading

Psychiatric TimesTM September 2021

Psychiatric TimesTM September 2021

Psychiatric Evaluation of the Peripartum Patient

The peripartum period is not necessarily a time of emotional well-being,1,2 highlighted by the fact that about 1 in 13 women develop new-onset major depressive disorder (MDD) while pregnant.3 (The term “peripartum” in this article refers to pregnant women and women who are up to 1 year postpartum.) In the postpartum period, 1 in 7 women will develop MDD and are at high risk for psychiatric hospitalization.4,5 Thus, comprehensive psychiatric evaluation of the peripartum patient is an essential skill. The mainstay of assessment remains the clinical interview; as such, careful and systematic psychiatric evaluation during these periods is crucial for diagnosis, risk assessment, and treatment. The general psychiatric evaluation, however, must be expanded and tailored to the needs of the peripartum patient. Continue Reading

Psychiatric TimesTM December 2021

Psychiatric TimesTM December 2021

Psychiatrists’ Response to Human Trafficking

Human trafficking is a public health issue that involves exploiting individuals for forced sex or labor. Traffickers perpetuate the cycle of exploitation by utilizing methods such as emotional, economic, or physical abuse; isolation; and threats. Physical, mental, legal, and social sequelae of human trafficking can persist for years after individuals survive their trafficking situations. Individuals with a preexisting history of psychiatric illnesses, including substance use disorders, are especially vulnerable to being trafficked. Continue Reading

Here is a full list of our CMEs from 2021:

January: Microglial Involvement With Psychiatric Diseases

February: Neuropsychiatric Symptoms of Multiple Sclerosis and Opportunities in Managing Treatment-Resistant Depression and Tardive Dyskinesia

March: Psilocybin Revisited: The Science Behind the Drug and Its Surprising Therapeutic Potential

April: Psychological and Cognitive Insight: How to Tell Them Apart and Assess for Each

May: Different Strokes: How to Spot and Treat Poststroke Depression

June: Transgenerational Transmission of Resilience After Catastrophic Trauma

July: Prognostic Considerations in Anti-NMDA Receptor Encephalopathy With Psychiatric Manifestations

August: Fibromyalgia: What It Is and How to Treat It

September: Psychiatric Evaluation of the Peripartum Patient

October: Personality Disorder and Dangerousness

November: Cognitive/Neuropsychological Functioning and Suicidal Behavior: A Review of Research and Implications for Clinical Practice

December: Psychiatrists’ Response to Human Trafficking

Be sure to stay up-to-date by subscribing to the Psychiatric TimesTM E-newsletter.

Do you have a comment on any of these or other articles? Have a good idea for an article and want to write? Interested in sharing your perspectives? Write to us at PTeditor@mmhgroup.com.

Related Videos
MLK
depression
Judaism
brain depression
brain
brain schizophrenia
eating disorder brain
brain
© 2024 MJH Life Sciences

All rights reserved.